We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Medical

Swisscann

Status: Funded

Oct 24th 2023 - Nov 23rd 2023

Swiss-licensed medical cannabis producer, swisscann, targets the expansive €12 billion global medical cannabis market, with an EU distribution agreement already secured. Leveraging its THC-licensed production facility, the company aims to meet the rising demand for safe and effective medical cannabis products, boasting a cultivation license and a partnership with a publicly listed European pharmaceutical distributor.

Strategically headquartered in Zurich, Switzerland, swisscann benefits from proximity to Germany, Europe's largest medical cannabis market projected to reach multibillion-Euro valuations by 2027. Anticipating availability in European pharmacies and an initial launch in the German market by Q1 2024, swisscann aims to establish its foothold in the European medical cannabis landscape.

read more read less
Log in to view amount pledged

    Log in to view target

    £9,260,000
    pre-money valuation

    8.41%
    equity available

    609
    investors

    £1,753
    pledge per investor

    Previous Funding rounds
    07 Dec 23 Seedrs £1,067,294 / 126%

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


Log in to view amount pledged

    Log in to view target

    £9,260,000
    pre-money valuation

    8.41%
    equity available

    609
    investors

    £1,753
    pledge per investor

    Previous Funding rounds
    07 Dec 23 Seedrs £1,067,294 / 126%
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph